The New Paper

October 8, 2020

Pharma companies seek emergency use authorization for coronavirus treatments

Pharmaceutical companies Eli Lilly and Regeneron requested emergency use authorization for separate coronavirus antibody treatments yesterday:

  • Eli Lilly requested authorization for its LY-CoV555 treatment after releasing promising results from initial trials last month. The company also announced plans to seek authorization for a combination therapy in November, noting that it reduced hospitalizations in initial trials.
  • Regeneron requested authorization for its REGN-COV2 treatment, which was one of several treatments received by President Trump after he was diagnosed with the coronavirus last week.

Extra: Here’s a tracker of vaccines and treatments currently in development.

This story is from the October 8, 2020 edition of The New Paper – a clear, concise daily briefing that makes fact-first news easy to consume. Try it today.